Currently out of the existing stock ratings of Andrew Tsai, 27 are a BUY (96.43%), 1 are a HOLD (3.57%).

Andrew Tsai

Work Performance Price Targets & Ratings Chart

Analyst Andrew Tsai, employed at JEFFERIES, carries an average stock price target met ratio of 31.67% that have a potential upside of 30.6% achieved within 119 days on average.

Andrew Tsai’s has documented 65 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VTGN, VistaGen Therapeutics at 07-Dec-2023.

Wall Street Analyst Andrew Tsai

Analyst best performing recommendations are on XENE (XENON PHARMACEUTICALS).
The best stock recommendation documented was for XENE (XENON PHARMACEUTICALS) at 8/30/2021. The price target of $28 was fulfilled within 35 days with a profit of $11.09 (65.58%) receiving and performance score of 18.74.

Average potential price target upside

ATHA Athira Pharma  ITCI Intracellular Th XENE Xenon Pharmaceuticals ATAI ATAI Life Sciences BV SAGE Sage Therapeutic VTGN VistaGen Therapeutics MRNS Marinus Pharmaceuticals RLMD Relmada Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

19

$16.4 (630.77%)

1 months 3 days ago

0/2 (0%)

$16.29 (601.11%)

Buy

5

$2.4 (92.31%)

6

1 years 1 months 4 days ago

0/3 (0%)

$2.13 (74.22%)

Buy

10

$7.4 (284.62%)

33

1 years 2 months 20 days ago

0/2 (0%)

$7.54 (306.50%)

Buy

3

$0.4 (15.38%)

32

1 years 11 months 27 days ago

2/5 (40%)

$0.25 (9.09%)

35

Buy

36

1 years 11 months 28 days ago

0/2 (0%)

$24.4 (210.34%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Andrew Tsai?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?